Get alerts for new trials in your area by subscribing now
Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.
Early stage trials. New antibody drug conjugates and immunotherapy combinations before or after surgery, tested against current standards in Phase 3.
Metastatic trials. Antibody drug conjugates as first treatment and in later lines.
Bispecific antibody trials. New immune drugs combined with chemotherapy in previously untreated advanced TNBC.
BRCA and targeted trials. PARP inhibitors and other drugs for tumors with DNA repair defects.
Supportive care and lifestyle trials. Exercise during immunotherapy, managing side effects, and survivorship.
Trials sort by stage and treatment history: early stage trials enroll people before or after surgery, often specifying whether cancer remained after chemotherapy, while metastatic trials specify how many prior treatments are allowed and whether PD-L1 or BRCA testing is required. Men with TNBC are eligible for most studies. Eligibility always varies by study.
Sometimes. People with an inherited BRCA1 mutation are more likely to develop TNBC than other breast cancers, which is why genetic testing is recommended for everyone diagnosed. Most cases are not inherited.
Early stage (I to III). Treated with intent to cure using chemotherapy and immunotherapy before surgery; trials test new drugs before surgery and treatment after it for cancer that remained.
Metastatic (IV). Spread to distant organs; trials test antibody drug conjugates and immunotherapy combinations by line of treatment.
Recurrent. Cancer that returned after early stage treatment, usually eligible for metastatic trials.
Identify your trial. Use the filters and match the stage or type and the treatment history named in study titles to your own.
Select your preferred location. Enter your city or state; large trials run at many sites, early phase studies at fewer centers.
Explore study details. Click "Learn More" for eligibility, prior treatment rules, and the visit schedule.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your stage and any PD-L1 or BRCA results, the treatments you have had and whether cancer remained after surgery, and your other health conditions.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step.